Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proof-of-concept studies with a computationally designed M inhibitor as a synergistic combination regimen alternative to Paxlovid.
Proc Natl Acad Sci U S A
April 2024
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520-8066.
As the SARS-CoV-2 virus continues to spread and mutate, it remains important to focus not only on preventing spread through vaccination but also on treating infection with direct-acting antivirals (DAA). The approval of Paxlovid, a SARS-CoV-2 main protease (M) DAA, has been significant for treatment of patients. A limitation of this DAA, however, is that the antiviral component, nirmatrelvir, is rapidly metabolized and requires inclusion of a CYP450 3A4 metabolic inhibitor, ritonavir, to boost levels of the active drug.
View Article and Find Full Text PDFIs Paxlovid Still Worth It?
Clin Infect Dis
July 2024
School of Health and Society, University of Wollongong, New South Wales, Australia.
IgA Vasculitis Associated With COVID-19.
Cureus
May 2023
Department of Rheumatology, Baylor Scott & White All Saints Medical Center, Fort Worth, USA.
IgA vasculitis, also known as Henoch-Schonlein Purpura (HSP), is an inflammatory disorder of small blood vessels that can present with palpable purpura, arthralgias, abdominal pain, and kidney disease. It is most commonly found in pediatric patients after an inciting infection but has been seen across all ages and associated with certain drugs and vaccines. COVID-19 has been associated with various cutaneous manifestations, but HSP is a rarely reported one.
View Article and Find Full Text PDFDiscovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2.
Bioorg Med Chem Lett
June 2023
WuXi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, People's Republic of China. Electronic address:
The outbreak of SARS-CoV-2 has caused global crisis on health and economics. The multiple drug-drug interaction risk associated with ritonavir warrants specialized assessment before using Paxlovid. Here we report a multiple-round SAR study to provide a novel bicyclic[3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!